Artiva Biotherapeutics (NASDAQ:ARTV) Upgraded by HC Wainwright to Buy Rating

Artiva Biotherapeutics (NASDAQ:ARTV) was upgraded by HC Wainwright to a “buy” rating in a research note issued to investors on Wednesday, Marketbeat.com reports. The firm presently has a $12.00 price objective on the stock.

ARTV has been the topic of several other reports. Needham & Company LLC reduced their price objective on Artiva Biotherapeutics from $23.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, May 15th. Cantor Fitzgerald dropped their target price on Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Tuesday, March 25th. Finally, Wedbush reaffirmed an “outperform” rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a research report on Tuesday, March 25th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $17.80.

Artiva Biotherapeutics Price Performance

Shares of NASDAQ ARTV opened at $1.96 on Wednesday. Artiva Biotherapeutics has a 52-week low of $1.78 and a 52-week high of $17.31. The business has a fifty day moving average of $2.14 and a two-hundred day moving average of $5.38.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.15). As a group, equities analysts forecast that Artiva Biotherapeutics will post -4.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several large investors have recently bought and sold shares of the stock. Wells Fargo & Company MN raised its position in shares of Artiva Biotherapeutics by 64.0% in the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock valued at $87,000 after acquiring an additional 3,361 shares during the period. BNP Paribas Financial Markets grew its holdings in shares of Artiva Biotherapeutics by 262.1% during the fourth quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company’s stock worth $100,000 after purchasing an additional 7,151 shares during the last quarter. Deutsche Bank AG bought a new stake in Artiva Biotherapeutics in the fourth quarter valued at approximately $216,000. Barclays PLC raised its position in shares of Artiva Biotherapeutics by 23.2% during the fourth quarter. Barclays PLC now owns 24,161 shares of the company’s stock worth $244,000 after purchasing an additional 4,545 shares during the period. Finally, Norges Bank bought a new position in Artiva Biotherapeutics in the 4th quarter valued at $302,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.